Biophytis SA and LynxKite Technologies have announced an expansion of their partnership focused on advancing artificial intelligence (AI)-driven drug discovery aimed at developing next-generation therapies for age-related conditions. This initiative, unveiled on March 13, 2026, includes the launch of new modalities beyond their existing project, MASSIVE, which stands for MAS Receptor Synthetic Innovation & Virtual Engineering for Sarcopenia therapy.
The collaboration will leverage a computational longevity platform that encompasses unique curated datasets and accelerated computation methods tailored for longevity research. Key areas of focus will include developing drug candidates targeting sarcopenia, a degenerative muscle disease prevalent among elderly populations, as well as therapies for dry age-related macular degeneration.
The strategic initiative is supported by Enterprise Singapore and aligns with Singapore’s Research, Innovation and Enterprise (RIE) 2030 plan, which prioritizes advancements in areas that can significantly impact public health.
Innovative AI Integration for Drug Development
LynxKite Technologies, recognized for its advanced analytics and AI capabilities, will incorporate cutting-edge computational methods relevant to longevity research into its platform. With a track record of supporting over 100 global enterprises, including major pharmaceutical companies like Roche and AstraZeneca, LynxKite’s team has substantial experience in utilizing graph-based and generative AI approaches for complex data analysis.
The MASSIVE project aims to identify and develop drug candidates that activate the Mas receptor (MasR), which is associated with muscle health. This degenerative condition affects millions, making the need for effective therapies urgent. Biophytis will contribute its extensive knowledge of age-related diseases and preclinical experience with MasR-linked conditions, enhancing the collaboration’s potential impact.
Strategic Goals and Future Developments
The objectives of this collaboration are ambitious. They include modeling the Mas receptor to facilitate structure-based drug design using AI and protein prediction tools. Additionally, the partners will prioritize and design synthetic drug candidates through AI-guided molecule generation and predictive filtering.
The project further encompasses the synthesis and testing of promising MasR activators to evaluate their biological activity, safety, and pharmacokinetics. A crucial phase involves protecting the lead candidate through patent filings, setting the stage for preclinical development. The AI software will also be refined through feedback from both in vitro and in vivo validation of the drug candidates.
“The launch of MASSIVE marks a decisive step in our longevity strategy, combining our clinical expertise with LynxKite’s innovative AI to accelerate the discovery of transformative therapies against sarcopenia,” stated Stanislas Veillet, CEO of Biophytis. Gyorgy Lajtai, CEO of LynxKite, expressed pride in the collaboration, emphasizing how their platform can revolutionize drug discovery by effectively integrating and orchestrating relevant computational tools across various modalities.
As the partnership progresses, it stands to significantly contribute to the field of longevity therapeutics, providing potential solutions for age-related diseases that affect millions worldwide.
For further information on this collaboration or to explore the technologies involved, please visit the respective websites of Biophytis and LynxKite Technologies.
